Company Kidswell Bio Corporation

Equities

4584

JP3386460004

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Ratings for Kidswell Bio Corporation

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Japan Exchange Other stock markets 10:11:50 2024-07-16 pm EDT			5-day change	1st Jan Change
147 ^JPY	+2.80%		+9.70%	+9.70%

2023	Kidswell Bio Corporation announced that it has received ¥22.8 million in funding from CVI Investments, Inc.	CI
2023	Kidswell Bio Corporation announced that it expects to receive Â¥22.8 million in funding from CVI Investments, Inc.	CI

Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

Number of employees: 38

JPY in Million	2023	Weight	2024	Weight	Delta
Biosimilars 99.8 %	2,573	92.7 %	2,426	99.8 %	-5.71%
Cell Therapy (Regenerative Medicine) 0.2 %	204	7.3 %	5	0.2 %	-97.34%

JPY in Million	2023	Weight	2024	Weight	Delta
Japan 100.0 %	2,776	100.0 %	2,431	100.0 %	-12.43%

Managers	Title	Age	Since
Yasuo Sakae ADM	Chief Administrative Officer	-	-
Masayuki Kawakami BRD	Director/Board Member	-	-
Osamu Sugawara AUD	Comptroller/Controller/Auditor	66	18-10-31

Members of the board	Title	Age	Since
Norikazu Eiki BRD	Director/Board Member	76	18-05-31
Masayuki Kawakami BRD	Director/Board Member	-	-
Aya Chiba BRD	Director/Board Member	38	20-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	39,406,213	25,279,423 ( 64.15 %)	94 ( 0.000239 %)	64.15 %

Name	Equities	%	Valuation
NORITSU KOKI CO., LTD. 24.04 %	9,471,832	24.04 %	8 M ¥
NANO MRNA CO.,LTD. 2.538 %	1,000,000	2.538 %	876 540 ¥
Koichi Otomo 2.125 %	837,450	2.125 %	734 058 ¥
JSR CORPORATION 1.743 %	686,814	1.743 %	602 020 ¥
Nine KK (TY) 1.573 %	620,000	1.573 %	543 455 ¥
Senju Pharmaceutical Co., Ltd. 1.409 %	555,200	1.409 %	486 655 ¥
Taro Koike 1.167 %	460,000	1.167 %	403 208 ¥
Chikamasa Tsuda 1.108 %	436,800	1.108 %	382 873 ¥
Shinya Kurebayashi 0.2208 %	87,000	0.2208 %	76 259 ¥
Heights Capital Management, Inc. 0.1611 %	63,466	0.1611 %	55 630 ¥

Name	Equities	%	Valuation
KIDSWELL BIO CORPORATION 0.00%	93	0.00%	82 $

Kidswell Bio Corp.

Kanayama Building, 3/F 1-2-12 Shinkawa

104-0033, Tokyo

http://www.kidswellbio.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

143 JPY

Average target price

800 JPY

Spread / Average Target

+459.44%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
KIDSWELL BIO CORPORATION	+6.72%	34.19M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs